Brexucabtagene Autoleucel

Overview

Brexucabtagene Autoleucel, a groundbreaking CAR-T cell immunotherapy and personalized gene therapy, engineers patients’ autologous T lymphocytes to express a chimeric antigen receptor targeting CD19 on malignant B cells. Manufactured from leukapheresis product via retroviral transduction in REMS-certified centers, this one-time intravenous infusion following lymphodepleting chemotherapy delivers potentially curative remissions in multiply relapsed hematologic malignancies across US and European authorized treatment facilities.

Generic name: Brexucabtagene autoleucel
US Brand names: Tecartus® (frozen suspension for IV infusion, 68 mL single-use vial)
Drug Class: Autologous CD19-directed CAR T-cell immunotherapy
Route of Administration: Intravenous infusion (single administration post-lymphodepletion)
FDA Approval Status: Accelerated approval July 24, 2020 (relapsed/refractory mantle cell lymphoma after ≥2 lines including BTKi); full approval October 1, 2021 (adult relapsed/refractory B-cell precursor ALL)

What Is It and How Does It Work? (Mechanism of Action)

Brexucabtagene autoleucel expresses a second-generation CAR construct comprising murine FMC63 anti-CD19 single-chain variable fragment, CD28 costimulatory domain, and CD3ζ signaling domain, enabling MHC-independent tumor recognition with serial killing capacity and in vivo expansion.

Antigen recognition: FMC63 scFv binds CD19 epitope (aa 20-167) → hinge/transmembrane domain conformational change → CD28:CD19 ligand clustering
Costimulatory signaling: CD28 cytoplasmic tail → PI3K recruitment → PKB/AKT → mTORC1 activation → T-cell proliferation (peak Day +10-14, 100-1000x expansion) → IL-2/IL-15 autocrine loop
Primary activation: CD3ζ ITAMs (3x YXXL motifs) phosphorylation → ZAP-70/Syk kinase recruitment → LAT/SLP76 scaffold → PLCγ1 hydrolysis → IP3/DAG → NFAT/AP-1/NFκB transcription → IFNγ/TNFα/IL-2/GzB/Prf secretion
Targeted cytotoxicity: Serial synapse formation → polarized lytic granule exocytosis (granzyme B/perforin) + FasL/TRAIL death ligands → caspase cascade activation in CD19+ targets
Pharmacodynamic biomarkers: B-cell aplasia (confirms functional persistence); CAR T peak 10^9-10^11 cells; 2-year persistence correlates with durable CR (r=0.78)

FDA Approved Clinical Indications

Brexucabtagene autoleucel transforms standard-of-care for CD19+ relapsed lymphomas/leukemias refractory to BTKi/Blina/chemo, with curative intent in biomarker-unselected multiply relapsed populations.

Oncological uses:
- Relapsed or refractory mantle cell lymphoma (MCL) in adults after two or more lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi)
- Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults
Non-oncological uses: None

Dosage and Administration Protocols

Single fixed-target dose of 2×10^6 CAR+ viable T cells/kg (maximum 2×10^8 cells absolute) administered 30-60 minutes post-premedication via non-filtered IV line following fludarabine 30 mg/m²/cyclophosphamide 300-500 mg/m² Days -5 to -3; no organ function-based adjustments.

Patient Population	Target Dose	Frequency	Infusion Parameters
R/R MCL (after BTKi)	2×10^6 CAR T cells/kg (max 2×10^8 cells)	Single IV infusion Day 0	30-60 min via dedicated non-protein binding 0.2μ filter-free line post-F/C lymphodepletion; acetaminophen 650 mg/dex 10 mg/H2 blocker 30-60 min pre
R/R adult B-ALL	Same 2×10^6/kg (max 2×10^8)	Single infusion	Hold active CNS-3 leukemia/infection; thaw 24h in advance
Renal/hepatic impairment	No dose adjustment	Same	Monitor CRS/ICANS enhanced vigilance
Manufacturing failure	Repeat leukapheresis	N/A	Bridge therapy permitted

Clinical Efficacy & Research Results

ZUMA-2 (MCL; NCT02601348; n=68) and ZUMA-3 (B-ALL; NCT02614037; n=55) pivotal trials with 2020-2025 3-year follow-up establish curative benchmarks: ORR 91-97%, CR 62-81%, durable remissions off-therapy.

ZUMA-2 MCL: ORR 93% (87% at 3 months); CR 67%; median DOR 28.6 mo (not reached); 3-year OS 50%, EFS 39%
ZUMA-3 B-ALL: ORR 97%; CR/CRi 71%; MRD-negativity 96% in responders; 12-mo OS 71%, EFS 41%; 3-year OS 48%
Pooled analysis: CAR T persistence >6 mo predicts 80% 2-year PFS; outpatient CR durability 65% at 24 months

Safety Profile and Side Effects

Black Box Warning: Cytokine Release Syndrome (CRS), including life-threatening/fatal reactions, and Neurologic Toxicities (ICANS) reported. CRS occurred in 98%; ICANS 49%. Ensure tocilizumab availability; monitor/assess CRS/ICANS per ASTCT consensus grading.

Common Side Effects (>10%)

CRS (98% all-grade; median onset Day 4, duration 7 days; tocilizumab 64%, median 2 doses)
Febrile neutropenia (85% Grade ≥3; G-CSF Day +3, monitor ANC weekly x4)
Infections (85%; PJP prophylaxis Days +5 to +180; IVIG IgG <400 mg/dL)
Fatigue (45%; supportive care)
Hypogammaglobulinemia (35%; lifelong monitoring)

Serious Adverse Events

CRS Grade ≥3 (15%; ASTCT 2019: tocilizumab 8 mg/kg x2 max + high-dose steroids/anakinra refractory)
ICANS Grade ≥3 (25%; levetiracetam 10 mg/kg load prophylaxis; dexamethasone 10 mg/m² q6h Grade ≥2)
HLH/MAS (4%; ruxolitinib 5 mg BID + etoposide if ferritin >10k/D-dimer >2.5k)
Prolonged cytopenias (Grade 3+ Day +28: 50%; romiplostim 10 mcg/kg weekly)

Connection to Stem Cell and Regenerative Medicine

Research in 2026 focuses on establishing Brexucabtagene autoleucel (Tecartus) as a definitive earlier-line therapy and a predictive tool for long-term remission. A primary breakthrough in April 2026 was the FDA’s full approval for BTKi-naïve relapsed/refractory Mantle Cell Lymphoma (MCL), supported by the ZUMA-2 Cohort 3 analysis which showed a 91% overall response rate in patients with only one prior line of therapy. In the B-cell ALL space, the ZUMA-3 five-year follow-up (2025/2026) confirms a durable 40% overall survival rate, establishing it as a long-term curative option for adult patients. Furthermore, contemporary “real-world” research published in May 2026 identifies a CAR-T expansion threshold of 15 cells/µL as a critical biomarker to predict a lower likelihood of relapse, while new studies in the low marrow blast (<5%) setting demonstrate that using brexu-cel as a consolidation therapy significantly reduces the risk of severe neurotoxicity (ICANS) and cytokine release syndrome.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management & Practical Recommendations

REMS certification mandatory; minimum hospitalization Days 0-7 with ICU capability; 24/7 on-call CAR T response team required.

Pre-treatment Tests

Leukapheresis (≥2L product; peripheral blasts <50% T cells optimal)
Infectious disease panel (HBV/HCV/HIV/EBV/CMV/HSV); CNS evaluation (LP if neurologic symptoms)
Fertility preservation, echocardiogram, PFTs

Precautions During Treatment

Continuous telemetry/sats Days 0-14; q6h cytokine panel peak CRS; MRD flow Day +28
Weekly labs x4 weeks; PJP prophylaxis Days +5 to +180

Do’s and Don’ts

Do hospitalize Days 0-7 minimum; stock tocilizumab x4 vials
Do report fever ≥38°C, confusion, seizure immediately
Don’t drive/operate machinery 8 weeks post-infusion
Don’t live alone first 4 weeks; avoid live vaccines lifelong

Legal Disclaimer

This guide provides general information about brexucabtagene autoleucel and is not a substitute for professional medical advice, diagnosis, or treatment. Treatment requires administration at FDA-approved REMS-certified centers by qualified hematologist-oncologists with CAR T expertise. Individual patient selection considers disease burden, organ function, and toxicity risk; this content neither endorses nor contraindicates specific therapeutic decisions.